Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-25T23:47:55.037Z Has data issue: false hasContentIssue false
  • English
  • Français

05-03 Disease burden of bipolar and schizoaffective disorder in an Australian cohort

Published online by Cambridge University Press:  24 June 2014

AR de Castella ,
M Berk ,
P Fitzgerald ,
S Filia ,
K Filia ,
S Tahtalian ,
S Dodd ,
P. Callaly ,
L Berk  and
K Kelin
...Show all authors
AR de Castella
Affiliation:
Alfred Psychiatry Research Centre, The Alfred and Monash University, School of Psychology, Psychiatry & Psychological Medicine, Melbourne, Australia
M Berk
Affiliation:
Department of Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, Australia
P Fitzgerald
Affiliation:
Alfred Psychiatry Research Centre, The Alfred and Monash University, School of Psychology, Psychiatry & Psychological Medicine, Melbourne, Australia
S Filia
Affiliation:
Alfred Psychiatry Research Centre, The Alfred and Monash University, School of Psychology, Psychiatry & Psychological Medicine, Melbourne, Australia
K Filia
Affiliation:
Alfred Psychiatry Research Centre, The Alfred and Monash University, School of Psychology, Psychiatry & Psychological Medicine, Melbourne, Australia
S Tahtalian
Affiliation:
Alfred Psychiatry Research Centre, The Alfred and Monash University, School of Psychology, Psychiatry & Psychological Medicine, Melbourne, Australia
S Dodd
Affiliation:
Department of Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, Australia
P. Callaly
Affiliation:
Department of Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, Australia
L Berk
Affiliation:
Department of Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, Australia
K Kelin
Affiliation:
Eli Lilly Australia Pty Ltd, Australia
M Smith
Affiliation:
School of Applied Social and Human Sciences, University of Western Sydney, Australia
A Brnabic
Affiliation:
Intercontinental Information Sciences, Eli Lilly Australia Pty Ltd, Australia
AJ Lowry
Affiliation:
Intercontinental Information Sciences, Eli Lilly Australia Pty Ltd, Australia
W Montgomery
Affiliation:
Eli Lilly Australia Pty Ltd, Australia
J Kulkarni
Affiliation:
Alfred Psychiatry Research Centre, The Alfred and Monash University, School of Psychology, Psychiatry & Psychological Medicine, Melbourne, Australia
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Abstracts from ‘Brainwaves’— The Australasian Society for Psychiatric Research Annual Meeting 2006, 6–8 December, Sydney, Australia
Information
Acta Neuropsychiatrica , Volume 18 , Issue 6 , December 2006 , pp. 325
Copyright
Copyright © 2006 Blackwell Munksgaard

Objective:

The Bipolar Comprehensive Outcomes Study (BCOS) is an ongoing, Australian, 2-year, observational study of participants with bipolar I or schizoaffective disorder, designed to examine the economic, clinical and functional outcomes associated with treatment in a ‘real-life’ context.

Methods:

Participants prescribed olanzapine or conventional mood stabilizers were assessed at entry using the Young Mania Rating Scale (YMRS), Hamilton Depression Rating Scale (HAMD21), Clinical Global Impressions Scale – Bipolar Version (CGI-BP) and the EuroQol Instrument.

Results:

On average, participants were 41.8 ± 12.7 years of age. About 58% (n = 140) were women, and 73% (n = 176) had a diagnosis of bipolar I disorder. Olanzapine was prescribed to 35% (n = 85) of participants, and more commonly for schizoaffective disorder (48% vs. 31% for bipolar). Based on CGI-BP scores, more women were markedly ill (34% vs. 22%, women vs. men) and significantly more depressed than men [HAMD21 total score 14.3 ± 8.7 vs. 12.1 ± 8.3, P = 0 .048; CGI-BP depression scores 3.5 ± 1.3 vs. 2.8 ± 1.3, P < 0 .001 (women vs. men)]. Participants were on average, hypomanic, with YMRS total and CGI-BP mania scores of 8.2 ± 8.5 and 3.0 ± 1.6, respectively. Bipolar participants rated their overall health state significantly higher than those with schizoaffective disorder. This trend was also reflected by the mean weekly wage ($500-$999, 21.3% vs. 6.3%, per cent participants, bipolar vs. schizoaffec-tive), unemployment rate (22.2% vs. 48.4%) and relationship status (47.1% vs. 26.6%, P = 0 .005).

Conclusions:

Participants were characterized by social and occupational dysfunction at study entry, but those with schizoaffective disorder appeared to be more severely affected. Effective treatment is required to address both clinical and functional impairment.